Comparative Pharmacology
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus TURGEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus TURGEX.
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE vs TURGEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine is a competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells. Calcium carbonate and magnesium hydroxide act as antacids, neutralizing gastric acid via chemical neutralization.
TURGEX is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin into presynaptic neurons.
1 tablet (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) orally once or twice daily as needed for heartburn; maximum 2 tablets in 24 hours.
10 mg orally once daily
None Documented
None Documented
Famotidine: 2.5-3.5 hours (prolonged in renal impairment, up to 20 hours when CrCl <10 mL/min).
Terminal half-life 8.2 ± 1.5 hours; extends to 15–20 hours in moderate hepatic impairment (Child-Pugh B) and to 12–14 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment
Famotidine: renal (65-70% unchanged), biliary/fecal (30-35%). Calcium carbonate: feces (unabsorbed calcium), urine (absorbed). Magnesium hydroxide: feces (unabsorbed magnesium), urine (absorbed).
Approximately 70% renal (60% unchanged, 10% as inactive glucuronide conjugate), 20% fecal via biliary elimination, and 10% metabolized by hepatic CYP3A4 to minor metabolites
Category A/B
Category C
Antacid / Laxative
Laxative